NMOSD

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided perspective on a phase 3 study of patients with NMOSD in which no relapses were recorded while on ravulizumab.

The associate professor of neurology at Harvard Medical School talked about the subgroup analysis on ravulizumab in NMOSD that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Inhibition of serum free complement 5 with ravulizumab was sustained throughout the treatment period according to a pharmacokinetics and pharmacodynamics analysis.

The treatment was superior in preventing on-trial relapse in both the monotherapy and immunosuppressive therapy groups compared with placebo in the CHAMPION-NMOSD trial.

Updated results to the phase 3 CHAMPION-NMOSD trial of ravulizumab showed significantly lower HAI score worsening following treatment.

NMOSD-related optic neuritis represented the strongest predictive risk factor of failure to attain visual recovery of at least 0.3 logMAR, with an odds ratio of 10.47.

An immunology fellow at Brigham and Women’s Hospital provided perspective on the positive impacts a new diagnostic criterion for MOGAD brings to the clinical community. [WATCH TIME: 4 minutes]

The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about his research of cell function in NMOSD to be presented at the upcoming AAN annual meeting. [WATCH TIME: 6 minutes]

Sheryl Lapidus, MA, senior director of patient advocacy at Horizon Therapeutics, talked about the findings from a recently conducted patient survey on NMOSD and the importance of advocacy in the field.

Michael Levy, MD, PhD, associate professor at Harvard Medical School, spoke about the breakthrough of drugs for NMOSD and the challenges patients face to receive treatment.

More than 95% of the cohort of elderly patients showed functional improvement at 6 months after plasma exchange, including 60% who experienced moderate-to-marked improvement.

Michael Levy, MD, PhD, associate professor at Harvard Medical School, talked about the differences between multiple sclerosis and neuromyelitis optica spectrum disorder, the currently available treatments, and next steps in research.

Disease activity, severity, or effect of treatment in patients with NMOSD may be predicted by aminoacyl-tRNA synthetase-interacting multifunctional protein-1.

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

Expression of CD16 and activation markers in natural killer and natural killer-T cells may be responsible for the escalating autoimmune activity in NMOSD.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided perspective on the sudden explosion of artificial intelligence, and how it can be applied to MS care.

At the 2023 ACTRIMS Forum, the clinical research director of the UCSF Multiple Sclerosis Center talked about the implications for patients on B-cell depleting therapies infected with COVID-19. [WATCH TIME: 4 minutes]

Nine of the 10 participants with NMOSD included in the case series have remained relapse-free after switching to satrlizumab from previous therapy.

The clinical research director of the UCSF Multiple Sclerosis Center spoke on the findings from two post-hoc analyses that were presented at the 2023 ACTRIMS Conference. [WATCH TIME: 3 minutes]

Of 2 patient fatalities in the analysis, one was unvaccinated and treated with nonconventional therapies for COVID-19 and the other had a history of deep venous thrombosis and was complicated by pulmonary embolism.

Bruce Cree, MD, PhD, MAS, FAAN, clinical research director of the UCSF Multiple Sclerosis Center provided insight on 2 post-hoc analyses of the N-MOmentum trial for NMOSD that were presented at 2023 ACTRIMS Forum.

A survey showed that 69% of patients with neuromyelitis optica spectrum disorders reported lost income because of hospital visits related to disease relapse.

Results from the open-label SAkuraMoon study show consistent relapse freedom in satralizumab-treated patients with aquaporin-4-IgG-seropositive NMOSD.

An analysis of patients with MOGAD showed that only 50% of those treated with various immunotherapies over a long-term period maintained relapse-free status.

The associate professor at Harvard Medical School spoke with NeurologyLive® about the differences between patients with multiple sclerosis and those with NMOSD. [WATCH TIME: 3 minutes]